Poseida Therapeutics (PSTX) News Today $9.31 -0.01 (-0.11%) (As of 11:58 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Poseida Therapeutics (NASDAQ:PSTX) Downgraded to "Neutral" Rating by Piper SandlerDecember 3 at 2:14 AM | americanbankingnews.comPoseida Therapeutics downgraded to Neutral from Overweight at Piper SandlerDecember 2 at 5:19 PM | markets.businessinsider.comRoche’s Acquisition Offer Leads to Hold Rating for Poseida Therapeutics Amid Promising Pipeline and Financial UncertaintiesDecember 2 at 12:18 PM | markets.businessinsider.comThe Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and NovartisDecember 2 at 7:15 AM | uk.finance.yahoo.comFred Alger Management LLC Buys Shares of 128,970 Poseida Therapeutics, Inc. (NASDAQ:PSTX)Fred Alger Management LLC purchased a new position in Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 128,970 shares of theDecember 2 at 5:09 AM | marketbeat.comPoseida Therapeutics' (PSTX) "Market Perform" Rating Reiterated at William BlairNovember 29, 2024 | americanbankingnews.comBTIG Research Reaffirms "Neutral" Rating for Poseida Therapeutics (NASDAQ:PSTX)November 29, 2024 | americanbankingnews.comPoseida Therapeutics (NASDAQ:PSTX) Cut to Hold at Cantor FitzgeraldNovember 29, 2024 | americanbankingnews.comPoseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Sells $278,100.00 in StockNovember 28, 2024 | insidertrades.comPoseida Therapeutics (NASDAQ:PSTX) Reaches New 52-Week High - Here's What HappenedNovember 28, 2024 | americanbankingnews.comConnor Clark & Lunn Investment Management Ltd. Grows Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX)Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) by 62.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 359,197 shares of the company's stock after buyNovember 28, 2024 | marketbeat.comPOSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida ...November 28, 2024 | businesswire.comPOSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTXNovember 27, 2024 | businesswire.comBTIG Downgrades Poseida Therapeutics (PSTX)November 27, 2024 | msn.comWilliam Blair downgrades Poseida Therapeutics (PSTX) to a HoldNovember 27, 2024 | markets.businessinsider.comPoseida Therapeutics (PSTX) was downgraded to a Hold Rating at BTIGNovember 27, 2024 | markets.businessinsider.comAdvantage Alpha Capital Partners LP Invests $285,000 in Poseida Therapeutics, Inc. (NASDAQ:PSTX)Advantage Alpha Capital Partners LP bought a new stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 99,566 shares of the compNovember 27, 2024 | marketbeat.comPoseida Therapeutics (NASDAQ:PSTX) Lowered to "Hold" Rating by Cantor FitzgeraldCantor Fitzgerald cut Poseida Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday.November 27, 2024 | marketbeat.comHC Wainwright Reiterates Neutral Rating for Poseida Therapeutics (NASDAQ:PSTX)November 27, 2024 | americanbankingnews.comPoseida Therapeutics Target of Unusually High Options Trading (NASDAQ:PSTX)November 27, 2024 | americanbankingnews.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTXNovember 26, 2024 | prnewswire.comWhy This Gene-Therapy Company's Stock Is Rising 228%November 26, 2024 | barrons.comRoche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 BillionNovember 26, 2024 | msn.comShareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public ShareholdersNovember 26, 2024 | businesswire.comHC Wainwright Reiterates "Neutral" Rating for Poseida Therapeutics (NASDAQ:PSTX)HC Wainwright reaffirmed a "neutral" rating and set a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a report on Tuesday.November 26, 2024 | marketbeat.comPSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to ShareholdersNovember 26, 2024 | businesswire.comRoche to acquire US-based Poseida TherapeuticsNovember 26, 2024 | reuters.comPoseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.November 26, 2024 | prnewswire.comPoseida Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comWhere Poseida Therapeutics Stands With AnalystsNovember 15, 2024 | benzinga.comPoseida Therapeutics (PSTX) Receives a Buy from Piper SandlerNovember 15, 2024 | markets.businessinsider.comPoseida Therapeutics (NASDAQ:PSTX) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Poseida Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comPoseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical PipelineNovember 14, 2024 | prnewswire.comPoseida Therapeutics to Present at Two Upcoming Investor ConferencesNovember 11, 2024 | prnewswire.comPoseida Therapeutics holds virtual R&D DayNovember 9, 2024 | markets.businessinsider.comPoseida Therapeutics Reports Strong Q3 2024 ProgressNovember 9, 2024 | markets.businessinsider.comPoseida Therapeutics' (PSTX) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Poseida Therapeutics in a research note on Friday.November 8, 2024 | marketbeat.comPoseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024November 7, 2024 | prnewswire.comPoseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024November 5, 2024 | prnewswire.comBuy Recommendation for Poseida Therapeutics: Harnessing Allogeneic CAR-T Technology for Autoimmune DiseasesOctober 31, 2024 | markets.businessinsider.comPoseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Poseida Therapeutics in a report on Wednesday.October 30, 2024 | marketbeat.comPoseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedemaOctober 24, 2024 | markets.businessinsider.comPoseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary AngioedemaOctober 24, 2024 | prnewswire.comPoseida Therapeutics, Inc.: Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with RocheOctober 17, 2024 | finanznachrichten.dePoseida Therapeutics Announces Nomination Of New Development Candidate Under Partnership With RocheOctober 17, 2024 | markets.businessinsider.comPoseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Poseida Therapeutics in a report on Thursday.October 17, 2024 | marketbeat.comPoseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with RocheOctober 17, 2024 | prnewswire.comPoseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024October 3, 2024 | prnewswire.comRenaissance Technologies LLC Acquires 297,500 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)Renaissance Technologies LLC raised its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) by 53.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 854,900 shares of the company's stock after purchasing an additional 297,500 shOctober 2, 2024 | marketbeat.comPoseida Therapeutics’ P-BCMA-ALLO-1 Shows Promising Efficacy and Safety in Phase I TrialsOctober 1, 2024 | markets.businessinsider.com Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. PSTX Media Mentions By Week PSTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTX News Sentiment▼0.300.87▲Average Medical News Sentiment PSTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTX Articles This Week▼343▲PSTX Articles Average Week Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRRK News Today MLTX News Today IBRX News Today AGIO News Today MRUS News Today ARWR News Today XENE News Today ZLAB News Today VERA News Today VRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poseida Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
